• Go to navigation
  • Go to content
AstraZeneca Clinical Trials

Astrazeneca Worldwide

  • AstraZeneca Websites
AstraZeneca US

Main navigation

  • Home
  • Therapy Areas
    • Oncology/Infection
    • Cardiovascular
    • Gastrointestinal
    • Neuroscience
    • Respiratory/Inflammation
  • Drug Products
    • All Drug Products
  • Diseases & Conditions
    • All Diseases and Conditions
  • Glossary
  • Contact Us
  • Disclosure Commitment

You are here

  • Home
  • Therapy Areas
  • Neuroscience
  • Trial of potentiation of antidepressive treatment in refractory depression: A comparison of Seroquel and Lithium.

Disease
schizophrenia
Drug Name
Seroquel
Generic Name
quetiapine
Sponsor
AstraZeneca
Drug Status
Approved Medicine
Phase
IIIb
Start Date
May 9, 2002
Study Name
5077/9003
Study Id
5077/9003
Recruiting Status
Closed
Protocol Status
Not Available
Report Status
Not Available

Page tools

  • Print
  • Bookmark this page

Legal notices

  • Legal notice
  • Privacy policy
  • © AstraZeneca 2013